-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Sunday, Immix Biopharma Says NXC-201 Shows 75% CR By Independent Review, With MRD Negativity Potentially Raising CR To 95%

Benzinga·12/08/2025 08:10:23
Listen to the news
  • NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –
  • In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% –
  • NEXICART-2 final readout and BLA submission planned in 2026 –